Loading…

Design of new potent hypolipidemic agents with the synergistic structural properties of α-asarone and fibrates

The series of bioisosteric analogs 9–17 were designed based on the potential pharmacophores of the highly hypolipidemic agents, α‐asarone (1), and fibrates such as clofibrate (2) and fenofibrate (3). These compounds are characterized by their simplicity, in terms of functional group diversity, becau...

Full description

Saved in:
Bibliographic Details
Published in:Drug development research 2005-01, Vol.64 (1), p.28-40
Main Authors: Zúñiga, Clara, Garduño, Leticia, del Carmen Cruz, María, Salazar, María, Pérez-Pastén, Ricardo, Chamorro, Germán, Labarrios, Fernando, Tamariz, Joaquín
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3688-cbb55a25552c1abd3869b59b49d13c9b4886485e4757427769e5d79a95386c373
cites cdi_FETCH-LOGICAL-c3688-cbb55a25552c1abd3869b59b49d13c9b4886485e4757427769e5d79a95386c373
container_end_page 40
container_issue 1
container_start_page 28
container_title Drug development research
container_volume 64
creator Zúñiga, Clara
Garduño, Leticia
del Carmen Cruz, María
Salazar, María
Pérez-Pastén, Ricardo
Chamorro, Germán
Labarrios, Fernando
Tamariz, Joaquín
description The series of bioisosteric analogs 9–17 were designed based on the potential pharmacophores of the highly hypolipidemic agents, α‐asarone (1), and fibrates such as clofibrate (2) and fenofibrate (3). These compounds are characterized by their simplicity, in terms of functional group diversity, because most of them are phenoxyacetic acids or their methyl and ethyl esters monosubstituted by an ethyl side‐chain at the ortho, meta, and para positions of the benzene ring. Despite this structural simplicity, these derivatives exhibited potent hypocholesterolemic activity, lowering the mice serum cholesterol and low‐density lipoprotein cholesterol levels up to 40% at the lowest dose of 25 mg/kg. These results supported the concept that the phenoxyacetic frame and the ethyl side‐chain can be considered as potent pharmacophores for the preparation of potential hypocholesterolemic drugs. Drug Dev. Res. 64:28–40, 2005. © 2005 Wiley‐Liss, Inc.
doi_str_mv 10.1002/ddr.10418
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17323410</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17323410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3688-cbb55a25552c1abd3869b59b49d13c9b4886485e4757427769e5d79a95386c373</originalsourceid><addsrcrecordid>eNp1kM1u1DAURi1EJYaWBW_gDUgs0vonju0l6kApqgChIiQ2luPczBgySerr0TCPxYv0mXCZAquuruV7vqOrj5DnnJ1yxsRZ16XyqLl5RBacWVMJYe1jsmBCi6qWlj8hTxG_M8Z5bcyCTEvAuBrp1NMRdnSeMoyZrvfzNMQ5drCJgfpV-UO6i3lN8xoo7kdIq4i57DCnbcjb5Ac6p2mGlCPgne32V-XRp2kE6seO9rFNPgOekKPeDwjP7ucx-fL2zfX5u-rq48Xl-eurKsjGmCq0rVJeKKVE4L7tpGlsq2xb247LUKYxTW0U1FrpWmjdWFCdtt6qQgap5TF5efCWq262gNltIgYYBj_CtEXHtRSy5qyArw5gSBNigt7NKW582jvO3F2lrlTq_lRa2Bf3Uo_BD33yY4j4P9BoVa6ShTs7cLs4wP5hoVsuP_81V4dEaRV-_kv49MM1Wmrlvn64cO8_SWW-2Wtn5G9_fJW_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17323410</pqid></control><display><type>article</type><title>Design of new potent hypolipidemic agents with the synergistic structural properties of α-asarone and fibrates</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Zúñiga, Clara ; Garduño, Leticia ; del Carmen Cruz, María ; Salazar, María ; Pérez-Pastén, Ricardo ; Chamorro, Germán ; Labarrios, Fernando ; Tamariz, Joaquín</creator><creatorcontrib>Zúñiga, Clara ; Garduño, Leticia ; del Carmen Cruz, María ; Salazar, María ; Pérez-Pastén, Ricardo ; Chamorro, Germán ; Labarrios, Fernando ; Tamariz, Joaquín</creatorcontrib><description>The series of bioisosteric analogs 9–17 were designed based on the potential pharmacophores of the highly hypolipidemic agents, α‐asarone (1), and fibrates such as clofibrate (2) and fenofibrate (3). These compounds are characterized by their simplicity, in terms of functional group diversity, because most of them are phenoxyacetic acids or their methyl and ethyl esters monosubstituted by an ethyl side‐chain at the ortho, meta, and para positions of the benzene ring. Despite this structural simplicity, these derivatives exhibited potent hypocholesterolemic activity, lowering the mice serum cholesterol and low‐density lipoprotein cholesterol levels up to 40% at the lowest dose of 25 mg/kg. These results supported the concept that the phenoxyacetic frame and the ethyl side‐chain can be considered as potent pharmacophores for the preparation of potential hypocholesterolemic drugs. Drug Dev. Res. 64:28–40, 2005. © 2005 Wiley‐Liss, Inc.</description><identifier>ISSN: 0272-4391</identifier><identifier>EISSN: 1098-2299</identifier><identifier>DOI: 10.1002/ddr.10418</identifier><identifier>CODEN: DDREDK</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Biological and medical sciences ; ethyl side-chain ; fibrates ; General and cellular metabolism. Vitamins ; hypocholesterolemia ; Medical sciences ; Pharmacology. Drug treatments ; phenoxyacetic frame ; α-asarone</subject><ispartof>Drug development research, 2005-01, Vol.64 (1), p.28-40</ispartof><rights>2005 Wiley‐Liss, Inc.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3688-cbb55a25552c1abd3869b59b49d13c9b4886485e4757427769e5d79a95386c373</citedby><cites>FETCH-LOGICAL-c3688-cbb55a25552c1abd3869b59b49d13c9b4886485e4757427769e5d79a95386c373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16756483$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Zúñiga, Clara</creatorcontrib><creatorcontrib>Garduño, Leticia</creatorcontrib><creatorcontrib>del Carmen Cruz, María</creatorcontrib><creatorcontrib>Salazar, María</creatorcontrib><creatorcontrib>Pérez-Pastén, Ricardo</creatorcontrib><creatorcontrib>Chamorro, Germán</creatorcontrib><creatorcontrib>Labarrios, Fernando</creatorcontrib><creatorcontrib>Tamariz, Joaquín</creatorcontrib><title>Design of new potent hypolipidemic agents with the synergistic structural properties of α-asarone and fibrates</title><title>Drug development research</title><addtitle>Drug Dev. Res</addtitle><description>The series of bioisosteric analogs 9–17 were designed based on the potential pharmacophores of the highly hypolipidemic agents, α‐asarone (1), and fibrates such as clofibrate (2) and fenofibrate (3). These compounds are characterized by their simplicity, in terms of functional group diversity, because most of them are phenoxyacetic acids or their methyl and ethyl esters monosubstituted by an ethyl side‐chain at the ortho, meta, and para positions of the benzene ring. Despite this structural simplicity, these derivatives exhibited potent hypocholesterolemic activity, lowering the mice serum cholesterol and low‐density lipoprotein cholesterol levels up to 40% at the lowest dose of 25 mg/kg. These results supported the concept that the phenoxyacetic frame and the ethyl side‐chain can be considered as potent pharmacophores for the preparation of potential hypocholesterolemic drugs. Drug Dev. Res. 64:28–40, 2005. © 2005 Wiley‐Liss, Inc.</description><subject>Biological and medical sciences</subject><subject>ethyl side-chain</subject><subject>fibrates</subject><subject>General and cellular metabolism. Vitamins</subject><subject>hypocholesterolemia</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>phenoxyacetic frame</subject><subject>α-asarone</subject><issn>0272-4391</issn><issn>1098-2299</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNp1kM1u1DAURi1EJYaWBW_gDUgs0vonju0l6kApqgChIiQ2luPczBgySerr0TCPxYv0mXCZAquuruV7vqOrj5DnnJ1yxsRZ16XyqLl5RBacWVMJYe1jsmBCi6qWlj8hTxG_M8Z5bcyCTEvAuBrp1NMRdnSeMoyZrvfzNMQ5drCJgfpV-UO6i3lN8xoo7kdIq4i57DCnbcjb5Ac6p2mGlCPgne32V-XRp2kE6seO9rFNPgOekKPeDwjP7ucx-fL2zfX5u-rq48Xl-eurKsjGmCq0rVJeKKVE4L7tpGlsq2xb247LUKYxTW0U1FrpWmjdWFCdtt6qQgap5TF5efCWq262gNltIgYYBj_CtEXHtRSy5qyArw5gSBNigt7NKW582jvO3F2lrlTq_lRa2Bf3Uo_BD33yY4j4P9BoVa6ShTs7cLs4wP5hoVsuP_81V4dEaRV-_kv49MM1Wmrlvn64cO8_SWW-2Wtn5G9_fJW_</recordid><startdate>200501</startdate><enddate>200501</enddate><creator>Zúñiga, Clara</creator><creator>Garduño, Leticia</creator><creator>del Carmen Cruz, María</creator><creator>Salazar, María</creator><creator>Pérez-Pastén, Ricardo</creator><creator>Chamorro, Germán</creator><creator>Labarrios, Fernando</creator><creator>Tamariz, Joaquín</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>200501</creationdate><title>Design of new potent hypolipidemic agents with the synergistic structural properties of α-asarone and fibrates</title><author>Zúñiga, Clara ; Garduño, Leticia ; del Carmen Cruz, María ; Salazar, María ; Pérez-Pastén, Ricardo ; Chamorro, Germán ; Labarrios, Fernando ; Tamariz, Joaquín</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3688-cbb55a25552c1abd3869b59b49d13c9b4886485e4757427769e5d79a95386c373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Biological and medical sciences</topic><topic>ethyl side-chain</topic><topic>fibrates</topic><topic>General and cellular metabolism. Vitamins</topic><topic>hypocholesterolemia</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>phenoxyacetic frame</topic><topic>α-asarone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zúñiga, Clara</creatorcontrib><creatorcontrib>Garduño, Leticia</creatorcontrib><creatorcontrib>del Carmen Cruz, María</creatorcontrib><creatorcontrib>Salazar, María</creatorcontrib><creatorcontrib>Pérez-Pastén, Ricardo</creatorcontrib><creatorcontrib>Chamorro, Germán</creatorcontrib><creatorcontrib>Labarrios, Fernando</creatorcontrib><creatorcontrib>Tamariz, Joaquín</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Drug development research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zúñiga, Clara</au><au>Garduño, Leticia</au><au>del Carmen Cruz, María</au><au>Salazar, María</au><au>Pérez-Pastén, Ricardo</au><au>Chamorro, Germán</au><au>Labarrios, Fernando</au><au>Tamariz, Joaquín</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design of new potent hypolipidemic agents with the synergistic structural properties of α-asarone and fibrates</atitle><jtitle>Drug development research</jtitle><addtitle>Drug Dev. Res</addtitle><date>2005-01</date><risdate>2005</risdate><volume>64</volume><issue>1</issue><spage>28</spage><epage>40</epage><pages>28-40</pages><issn>0272-4391</issn><eissn>1098-2299</eissn><coden>DDREDK</coden><abstract>The series of bioisosteric analogs 9–17 were designed based on the potential pharmacophores of the highly hypolipidemic agents, α‐asarone (1), and fibrates such as clofibrate (2) and fenofibrate (3). These compounds are characterized by their simplicity, in terms of functional group diversity, because most of them are phenoxyacetic acids or their methyl and ethyl esters monosubstituted by an ethyl side‐chain at the ortho, meta, and para positions of the benzene ring. Despite this structural simplicity, these derivatives exhibited potent hypocholesterolemic activity, lowering the mice serum cholesterol and low‐density lipoprotein cholesterol levels up to 40% at the lowest dose of 25 mg/kg. These results supported the concept that the phenoxyacetic frame and the ethyl side‐chain can be considered as potent pharmacophores for the preparation of potential hypocholesterolemic drugs. Drug Dev. Res. 64:28–40, 2005. © 2005 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><doi>10.1002/ddr.10418</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0272-4391
ispartof Drug development research, 2005-01, Vol.64 (1), p.28-40
issn 0272-4391
1098-2299
language eng
recordid cdi_proquest_miscellaneous_17323410
source Wiley-Blackwell Read & Publish Collection
subjects Biological and medical sciences
ethyl side-chain
fibrates
General and cellular metabolism. Vitamins
hypocholesterolemia
Medical sciences
Pharmacology. Drug treatments
phenoxyacetic frame
α-asarone
title Design of new potent hypolipidemic agents with the synergistic structural properties of α-asarone and fibrates
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A44%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20of%20new%20potent%20hypolipidemic%20agents%20with%20the%20synergistic%20structural%20properties%20of%20%CE%B1-asarone%20and%20fibrates&rft.jtitle=Drug%20development%20research&rft.au=Z%C3%BA%C3%B1iga,%20Clara&rft.date=2005-01&rft.volume=64&rft.issue=1&rft.spage=28&rft.epage=40&rft.pages=28-40&rft.issn=0272-4391&rft.eissn=1098-2299&rft.coden=DDREDK&rft_id=info:doi/10.1002/ddr.10418&rft_dat=%3Cproquest_cross%3E17323410%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3688-cbb55a25552c1abd3869b59b49d13c9b4886485e4757427769e5d79a95386c373%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17323410&rft_id=info:pmid/&rfr_iscdi=true